Coronavirus vaccines? Kulkarni and Boulanger weigh in on lofty goals
May 20, 2020
Can pharma meet its lofty goals for coronavirus vaccine production?
“What they would target with a typical pandemic, like influenza, is making 50 million doses at a plant within six months facilities that mass produce cGMP mRNA vaccines. To design, build and validate a new plant…you’re talking two years. And we don’t have that kind of time. But to convert? Assuming it’s a perfect scenario…you probably need six months.”
“It’s going to take several months to acquire the raw materials to make a new vaccine. Almost all of these products have very specialized raw materials…any one of these could have a long lead time. So you’d want to be on the phone with whoever makes your growth media, for example, to secure a supply.”
“Depending on the customization and automation needed, procuring, installing and running filling equipment can go all the way up to two years in lead time. So you need to find facilities with the right technology tailored to what you’re filling.”